Cancer Biomarkers: Are We Ready for the Prime Time?
暂无分享,去创建一个
[1] P. Hitchen,et al. Targeted glycoproteomic identification of cancer cell glycosylation , 2009, Glycobiology.
[2] A. Partin,et al. Antibody array profiling reveals serum TSP‐1 as a marker to distinguish benign from malignant prostatic disease , 2007, The Prostate.
[3] A. Simpson,et al. Detection of oral and oropharyngeal cancer by microsatellite analysis in mouth washes and lesion brushings. , 2000, Oral oncology.
[4] Margaret E McLaughlin-Drubin,et al. Viruses associated with human cancer. , 2008, Biochimica et biophysica acta.
[5] W. Funkhouser,et al. Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma. , 2004, Archives of otolaryngology--head & neck surgery.
[6] E. Van Cutsem,et al. Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial , 2009, Clinical Cancer Research.
[7] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[8] J. Gray,et al. Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities , 2008, Clinical Cancer Research.
[9] A. Melman,et al. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. , 1995, Nature medicine.
[10] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[11] T. Orntoft,et al. Clinical aspects of altered glycosylation of glycoproteins in cancer , 1999, Electrophoresis.
[12] Kit S Lam,et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. , 2006, Journal of proteome research.
[13] S. Chew,et al. Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix , 2002, British Journal of Cancer.
[14] Jeffrey T. Chang,et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential , 2009, Proceedings of the National Academy of Sciences.
[15] D. Saluja,et al. Differential expression and activation of NF‐κB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection , 2006 .
[16] Pauline M. Rudd,et al. Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis , 2009, Disease markers.
[17] Nan Hu,et al. 2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.
[18] M. Stoneham. Electrons in carbon country , 2004, Nature materials.
[19] T. Isono,et al. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma , 2009, International journal of urology : official journal of the Japanese Urological Association.
[20] M. Boxus,et al. Mechanisms of HTLV-1 persistence and transformation , 2009, British Journal of Cancer.
[21] Benjamin Geiger,et al. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.
[22] C. Van Waes,et al. cDNA microarray and bioinformatic analysis of nuclear factor-kappaB related genes in squamous cell carcinoma. , 2007, Methods in molecular biology.
[23] B. Zetter,et al. Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.
[24] Mukesh Verma,et al. Proteomics for Cancer Biomarker Discovery , 2002 .
[25] M. Loda,et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. O’Donovan,et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears , 2003, Journal of clinical pathology.
[27] J. Hirst,et al. Analysis of the Subunit Composition of Complex I from Bovine Heart Mitochondria*S , 2003, Molecular & Cellular Proteomics.
[28] H. Hausen. Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.
[29] T. Barrette,et al. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.
[30] C. Bertozzi,et al. Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.
[31] Shigeki Shimizu,et al. [Molecular abnormalities in lung cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.
[32] D. McCarthy,et al. Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer , 2004, Disease markers.
[33] S. Gygi,et al. Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research*S , 2004, Molecular & Cellular Proteomics.
[34] Caroline Seydel,et al. Quantum Dots Get Wet , 2003, Science.
[35] E. Masini,et al. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck , 2002, Cancer.
[36] J. Ajani,et al. Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. , 2009, American journal of translational research.
[37] S. Nelson,et al. DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.
[38] M. Verma,et al. Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.
[39] S. D. Lee,et al. Utility of lentil lectin affinity of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. , 1996, Journal of hepatology.
[40] Ji Huang,et al. [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.
[41] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[42] J. Gray,et al. Genome changes and gene expression in human solid tumors. , 2000, Carcinogenesis.
[43] J. Weinstein,et al. Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.
[44] B. Furie,et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. , 1984, The New England journal of medicine.
[45] P. Carroll,et al. CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate Cancer , 2004, Cancer Research.
[46] G. Lippi,et al. Prostate-specific antigen, prostate cancer, and disorders of hemostasis. , 2009, Seminars in thrombosis and hemostasis.
[47] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[48] F. Montorsi,et al. Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study , 2009, Clinical Cancer Research.
[49] Daisy R. Lee,et al. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[50] Meeting report: mitochondrial DNA and cancer epidemiology. , 2007, Cancer research.
[51] Rajiv Dhir,et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. , 2005, Cancer research.
[52] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[53] B. Weigl,et al. Lab-on-a-chip for drug development. , 2003, Advanced drug delivery reviews.
[54] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[55] Y. Mechref,et al. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. , 2009, Journal of proteome research.
[56] H. Banerjee,et al. Use of nanotechnology for the development of novel cancer biomarkers , 2006, Expert review of molecular diagnostics.
[57] Samir Gupta,et al. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. , 2003, Annals of internal medicine.
[58] J. McDougall,et al. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. , 1998, The American journal of pathology.
[59] Mukesh Verma,et al. Proteomic maps of the cancer-associated infectious agents. , 2005, Journal of proteome research.
[60] H. Keer,et al. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.
[61] M. Verma,et al. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. , 2006, Critical reviews in oncology/hematology.
[62] D. Katsaros,et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. , 2003, Cancer research.
[63] M. Kattan,et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] M. Verma. Biomarkers for Risk Assessment in Molecular Epidemiology of Cancer , 2004, Technology in cancer research & treatment.
[65] Michael W Kattan,et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] F. Gilliland,et al. Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.
[67] D. Dinulescu,et al. Focused glycomic analysis of the N‐linked glycan biosynthetic pathway in ovarian cancer , 2008, Proteomics.
[68] 王晓燕. Arch Intern Med:住院增加老年人出院后骨折危险 , 2009 .
[69] R. Aggarwal,et al. Plasma and urine biomarkers in acute viral hepatitis E , 2009, Proteome Science.
[70] S. Shenouda,et al. MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.
[71] Mukesh Verma,et al. The promise of biomarkers in cancer screening and detection. , 2002, Trends in molecular medicine.
[72] Phil Gold,et al. DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.
[73] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[74] Baruch S Blumberg,et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[75] D. Seminara,et al. Genetic and Epigenetic Biomarkers in Cancer , 2012, Molecular Diagnosis & Therapy.
[76] Samir Gupta,et al. Test Characteristics of -Fetoprotein for Detecting Hepatocellular Carcinoma in Patients with Hepatitis C , 2003, Annals of Internal Medicine.
[77] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[78] S. Rodenhuis,et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.
[79] D. Saluja,et al. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. , 2006, International journal of cancer.
[80] V. Bettinardi,et al. [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[81] Brian J Zikmund-Fisher,et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). , 2009, Archives of internal medicine.
[82] M. Verma. Pancreatic Cancer Epidemiology , 2005, Technology in cancer research & treatment.
[83] G. Tsongalis,et al. MicroRNAs: novel biomarkers for human cancer. , 2009, Clinical chemistry.
[84] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[85] R. Brakenhoff,et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[86] Mukesh Verma,et al. Proteomic analysis of cancer-cell mitochondria , 2003, Nature Reviews Cancer.
[87] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] Jicai Zhang,et al. Hypermethylation of Tumor Suppressor Genes BRCA1, p16 and 14-3-3s in Serum of Sporadic Breast Cancer Patients , 2007, Oncology Research and Treatment.
[89] Shou-Dong Lee,et al. Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma , 1996 .
[90] G. Zheng,et al. Optical Molecular Imaging: From Single Cell to Patient , 2008, Clinical pharmacology and therapeutics.
[91] J. Chin,et al. NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients. , 2009, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[92] C. Sawyers. The cancer biomarker problem , 2008, Nature.
[93] B. Vikram. The PSA conundrum. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[94] D. Ferrigno,et al. Lung tumour markers in oncology practice: a study of TPA and CA125 , 2002, British Journal of Cancer.
[95] M. Yanada. [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[96] Ram D. Sriram,et al. Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system. , 2004, Mitochondrion.
[97] C. O'Morain,et al. Helicobacter pylori Infection , 1994 .
[98] H. Nisenbaum,et al. HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.
[99] M. Verma,et al. Available online at www.sciencedirect.com R , 2002 .
[100] Shou-Dong Lee,et al. Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma , 1984 .
[101] J. Christensen,et al. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.
[102] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[103] M. Barry,et al. PSA screening for prostate cancer: the current controversy--a viewpoint. Patient Outcomes Research Team for Prostatic Diseases. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[104] M. Verma,et al. Application of mitochondrial genome information in cancer epidemiology. , 2007, Clinica chimica acta; international journal of clinical chemistry.
[105] J. Lafitte,et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.
[106] R. Dahiya,et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. , 2004, Biochemical and biophysical research communications.
[107] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.
[108] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[109] M. Ohue,et al. Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. , 2009, Journal of proteome research.
[110] H. Kimura,et al. Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. , 2003, European journal of biochemistry.
[111] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] D. Welch,et al. Metastamir: the field of metastasis-regulatory microRNA is spreading. , 2009, Cancer research.
[113] B. Seshi. An integrated approach to mapping the proteome of the human bone marrow stromal cell , 2006, Proteomics.
[114] H. Friess,et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders , 2001, Gut.
[115] B. King,et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer , 2005, Journal of Clinical Pathology.